Dr. Peter E. Clark, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 227
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Harvard Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
NC license 200200506
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Carolinas Medical Center/behav Health Charlotte, NC
- Carolinas Medical Center-Northeast Concord, NC
- Atrium Health Pineville Charlotte, NC
- Atrium Health Union Monroe, NC
- Atrium Health Cleveland Shelby, NC
Medical groups
- Carolinas Medical Center (1,067 clinicians)
- The Charlotte-Mecklenburg Hospital Authority (601 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 227
- Services billed
- 738
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Diagnostic exam of bladder and urethra using an endoscope | 155 | 82 |
| Established patient office or other outpatient visit, 20-29 minutes | 69 | 62 |
| Established patient office or other outpatient visit, 30-39 minutes | 41 | 32 |
| Telephone medical discussion with physician, 11-20 minutes | 28 | 22 |
| Imaging of urinary tract following injection of a contrast agent | 23 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 22 | 22 |
| Established patient office or other outpatient visit, 10-19 minutes | 20 | 19 |
| Insertion of stent in ureter using an endoscope | 19 | 13 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 18 | 16 |
| Telephone medical discussion with physician, 5-10 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Charlotte, NC | 71 |
| Myrbetriq (mirabegron) Other prescribers in Charlotte, NC | 31 |
| Trospium Chloride Other prescribers in Charlotte, NC | 31 |
| Finasteride Other prescribers in Charlotte, NC | 17 |
| Diazepam Other prescribers in Charlotte, NC | 14 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Charlotte, NC | 14 |
| Ciprofloxacin Hcl Other prescribers in Charlotte, NC | 12 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Charlotte, NC | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $133 in total to this clinician.
| Urogen Pharma, Inc. | $74.24 |
|---|---|
| Boston Scientific Corporation | $58.65 |
| Food and Beverage | $133 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $13,169 in research payments for these studies, mostly to the institutions running them.
- A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible …
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.